# Anika Therapeutics (ANIK) — Earnings

ANIK · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/anik/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.42 |
| EPS estimate | −$0.08 |
| EPS surprise | +625.00% |
| Revenue surprise | +11.62% |
| Revenue | $32.6M |
| Revenue estimate | $29.2M |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/898437/000117184326005012/anik20260630_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/75e711ff-da17-b32b-ef41-2c9890b7e390.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | −$0.08 | $0.42 | 625.00% | $29.2M | $32.6M |
| Q1 2026 | Apr 29, 2026 | −$0.07 | $0.27 | 485.71% | $28.1M | $29.6M |
| Q4 2025 | Feb 26, 2026 | −$0.13 | $0.31 | 348.00% | $28.9M | $30.6M |
| Q3 2025 | Nov 5, 2025 | −$0.18 | $0.04 | 122.22% | $27.8M | $27.8M |
| Q2 2025 | Jul 30, 2025 | −$0.26 | −$0.13 | 50.63% | $27.0M | $28.2M |
| Q1 2025 | May 9, 2025 | −$0.09 | −$0.06 | 33.33% | $28.1M | $26.2M |
| Q4 2024 | Mar 12, 2025 | −$0.23 | −$0.03 | 86.67% | $29.0M | $30.6M |
| Q3 2024 | Oct 31, 2024 | $0.09 | −$0.25 | -377.78% | $42.1M | $38.8M |
| Q2 2024 | Aug 8, 2024 | $0.07 | $0.17 | 154.87% | $40.8M | $41.9M |
| Q1 2024 | May 8, 2024 | −$0.08 | $0.09 | 212.50% | $39.1M | $40.5M |
| Q4 2023 | Mar 13, 2024 | −$0.23 | $0.05 | 122.06% | $41.4M | $43.0M |
| Q3 2023 | Nov 2, 2023 | −$0.35 | $0.00 | 100.00% | $38.3M | $41.5M |
| Q2 2023 | Aug 8, 2023 | −$0.32 | $0.06 | 118.75% | $40.4M | $44.3M |
| Q1 2023 | May 9, 2023 | −$0.34 | −$0.36 | -5.88% | $37.4M | $37.9M |
| Q4 2022 | Mar 6, 2023 | −$0.24 | −$0.34 | -41.67% | $37.7M | $39.6M |
| Q3 2022 | Nov 8, 2022 | −$0.25 | −$0.29 | -16.00% | $37.6M | $40.3M |
| Q2 2022 | Aug 3, 2022 | −$0.23 | −$0.20 | 11.78% | $37.9M | $39.7M |
| Q1 2022 | May 5, 2022 | −$0.33 | −$0.20 | 39.99% | $32.9M | $36.7M |
| Q4 2021 | Mar 8, 2022 | −$0.28 | −$0.40 | -41.19% | $32.1M | $35.8M |
| Q3 2021 | Nov 4, 2021 | −$0.21 | $0.04 | 119.03% | $36.3M | $39.5M |

## Frequently Asked Questions

### When did Anika Therapeutics (ANIK) last report earnings?

Anika Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did ANIK beat earnings estimates?

Yes. Anika Therapeutics reported EPS of $0.42 for Q2 2026 against a −$0.08 estimate — a 625.00% beat.

### How much revenue did ANIK report last quarter?

Anika Therapeutics reported $32.6M in revenue for Q2 2026, against a consensus estimate of $29.2M.

## Similar Stocks

- [ANVS](https://www.lighthorse.io/tickers/anvs) — Annovis Bio, Inc. Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).